These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 11583733

  • 1. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 2. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
    Wada H, Nobori T, Watanabe R, Shiku H, Sakuragawa N.
    Turk J Haematol; 2002 Jun 05; 19(2):235-7. PubMed ID: 27264764
    [Abstract] [Full Text] [Related]

  • 3. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T, Gando S, Mizugaki A, Yanagida Y, Jesmin S, Yokota H, Ieko M.
    Thromb Res; 2013 Jul 05; 132(1):e64-9. PubMed ID: 23726093
    [Abstract] [Full Text] [Related]

  • 4. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
    Hayakawa M, Sawamura A, Gando S, Jesmin S, Naito S, Ieko M.
    Thromb Res; 2012 Dec 05; 130(6):906-13. PubMed ID: 22353215
    [Abstract] [Full Text] [Related]

  • 5. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
    Watanabe R, Wada H, Miura Y, Murata Y, Watanabe Y, Sakakura M, Okugawa Y, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Shiku H, Nobori T.
    Clin Appl Thromb Hemost; 2001 Jul 05; 7(3):229-33. PubMed ID: 11441985
    [Abstract] [Full Text] [Related]

  • 6. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
    Chen CC, Lee KD, Gau JP, Yu YB, You JY, Lee SC, Hsu HC, Chau WK, Ho CH.
    Ann Hematol; 2005 Oct 05; 84(10):675-80. PubMed ID: 16007424
    [Abstract] [Full Text] [Related]

  • 7. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM, Taylor FB, Peer G, Bajzar L.
    Blood; 2007 Nov 01; 110(9):3168-75. PubMed ID: 17644733
    [Abstract] [Full Text] [Related]

  • 8. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.
    Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Nakao S.
    Crit Care Med; 2001 Jun 01; 29(6):1164-8. PubMed ID: 11395595
    [Abstract] [Full Text] [Related]

  • 9. Hemostatic molecular markers before the onset of disseminated intravascular coagulation.
    Wada H, Sakuragawa N, Mori Y, Takagi M, Nakasaki T, Shimura M, Hiyoyama K, Nisikawa M, Gabazza EC, Deguchi K, Kazama M, Shiku H.
    Am J Hematol; 1999 Apr 01; 60(4):273-8. PubMed ID: 10203100
    [Abstract] [Full Text] [Related]

  • 10. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group.
    Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H.
    Thromb Haemost; 1995 Sep 01; 74(3):848-52. PubMed ID: 8571309
    [Abstract] [Full Text] [Related]

  • 11. Hemostatic study before onset of disseminated intravascular coagulation.
    Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi A, Mori Y, Deguchi K.
    Am J Hematol; 1993 Jul 01; 43(3):190-4. PubMed ID: 8352234
    [Abstract] [Full Text] [Related]

  • 12. Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: determination of prothrombin fragment 1 + 2 and other markers.
    Okamoto K, Takaki A, Takeda S, Katoh H, Ohsato K.
    Haemostasis; 1992 Jul 01; 22(1):17-24. PubMed ID: 1387863
    [Abstract] [Full Text] [Related]

  • 13. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
    Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F.
    Tumour Biol; 2012 Oct 01; 33(5):1519-25. PubMed ID: 22535370
    [Abstract] [Full Text] [Related]

  • 14. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, Nishikawa M, Shiku H, Nobori T.
    Am J Hematol; 2003 Jan 01; 72(1):1-7. PubMed ID: 12508260
    [Abstract] [Full Text] [Related]

  • 15. Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
    Koyama T, Kakishita E, Nakai Y, Okamoto E.
    Am J Hematol; 1991 Oct 01; 38(2):90-4. PubMed ID: 1719808
    [Abstract] [Full Text] [Related]

  • 16. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
    Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2001 Aug 01; 16(8):1692-6. PubMed ID: 11477176
    [Abstract] [Full Text] [Related]

  • 17. An evaluation of circulating activated TAFI in septic DIC: a case series and review of the literature.
    Totoki T, Ito T, Kakuuchi M, Yashima N, Maruyama I, Kakihana Y.
    Thromb J; 2022 Feb 07; 20(1):6. PubMed ID: 35130927
    [Abstract] [Full Text] [Related]

  • 18. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
    Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A.
    J Thromb Haemost; 2008 Feb 07; 6(2):268-76. PubMed ID: 18021301
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 07; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 20. Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
    Velasco F, Torres A, Rojas R, Alvarez MA, Gomez P, Castillo D.
    Haemostasis; 1992 Aug 07; 22(3):117-23. PubMed ID: 1427455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.